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Vaccine adjuvantsa b s t r a c t
A novel coronavirus (CoV), Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), emerged in
late 2019 in Wuhan, China and has since spread as a global pandemic. Safe and effective vaccines are thus
urgently needed to reduce the significant morbidity and mortality of Coronavirus Disease 2019 (COVID-
19) disease and ease the major economic impact. There has been an unprecedented rapid response by
vaccine developers with now over one hundred vaccine candidates in development and at least six hav-
ing reached clinical trials. However, a major challenge during rapid development is to avoid safety issues
both by thoughtful vaccine design and by thorough evaluation in a timely manner. A syndrome of ‘‘dis-
ease enhancement” has been reported in the past for a few viral vaccines where those immunized suf-
fered increased severity or death when they later encountered the virus or were found to have an
increased frequency of infection. Animal models allowed scientists to determine the underlying mecha-
nism for the former in the case of Respiratory syncytial virus (RSV) vaccine and have been utilized to
design and screen new RSV vaccine candidates. Because some Middle East respiratory syndrome
(MERS) and SARS-CoV-1 vaccines have shown evidence of disease enhancement in some animal models,
this is a particular concern for SARS-CoV-2 vaccines. To address this challenge, the Coalition for Epidemic
Preparedness Innovations (CEPI) and the Brighton Collaboration (BC) Safety Platform for Emergency
vACcines (SPEAC) convened a scientific working meeting on March 12 and 13, 2020 of experts in the field








1. Introduction 2. Animal models of SARS-CoV-1 and MERS CoVSince the identification of a novel coronavirus, SARS-CoV-2, as
the cause of pneumonia in patients fromWuhan China, a pandemic
has erupted, resulting in enormous health care, social and eco-
nomic disruption to our global society [1]. As of May 17, 2020 there
have been 4,708,415 cases and 314,950 deaths worldwide [2]. In
rapid response to the pandemic, academic and industry scientists
from around the world have initiated efforts to develop vaccines
and therapeutics for disease prevention and patient management.
The Coalition for Epidemic Preparedness Innovations (CEPI), a glo-
bal partnership between public, private, philanthropic, and civil
organizations, is funding work to develop SARS-CoV-2 vaccines
using a variety of technology platforms. Several vaccine candidates
are already in Phase 1 studies with others likely to enter the clinic
in the next few months [3].
One of the challenges facing rapid vaccine development for
SARS-CoV-2 is the need to adequately assure the safety of these
vaccines. One such safety concern is disease enhancement syn-
drome that occurred in the 1960s with inactivated RSV and
measles vaccines. Vaccine-mediated disease enhancement is char-
acterized by a vaccine that results in increased disease severity if
the subject is later infected by the natural virus. During early trials
with inactivated RSV vaccine, the vaccine did not prevent infection,
80% of those infected required hospitalization and two children
died [4]. Lung pathology in patients showed an unexpected inflam-
matory response with both neutrophils and eosinophils, evidence
of immune complex formation and complement activation in small
airways [5]. Scientists later learned that the vaccine caused a sim-
ilar disease enhancement in animals characterized by
immunopathology and a T helper cell type 2 (Th2) biased response
and antibody responses with poor neutralizing activity [6–8]. Since
that time, the animal models have been relied upon to predict
safety for new RSV vaccines that are developed. Of note, the patho-
genesis of RSV disease enhancement is distinct from antibody dis-
ease enhancement (ADE) which occurs for macrophage tropic
viruses, demonstrated most notably for Dengue in humans and
the coronavirus feline infectious peritonitis virus in cats, and is
directly caused by non-neutralizing or sub-neutralizing antibodies
leading to more efficient viral uptake via Fcc receptor binding [9].
Since pathology consistent with the RSV vaccine enhanced dis-
ease (and perhaps ADE) has been demonstrated for some SARS-
CoV-1 vaccine candidates in animal models, there is also a concern
that a similar syndrome could occur in humans immunized with
SARS-CoV-2 candidate vaccines. Therefore, CEPI and the Brighton
Collaboration Safety Platform for Emergency vACcines (SPEAC)
convened a scientific working meeting https://brightoncollabora-
tion.us/brighton-collaboration-cepi-covid-19-web-conference/) on
March 12 and 13, 2020 of experts in the field of vaccine immunol-
ogy and coronaviruses to discuss current knowledge that could
form the basis for the assessment of the risk of enhanced disease
during SARS-CoV-2 vaccine development. This consensus report
presents considerations for vaccine developers and can serve as a
guide for the development and testing of vaccine candidates to
avoid these safety concerns. Ultimately, the door to clinical trials
is controlled by regulators in the context of the risk/benefit for
the entire dataset provided by developers and within the local trial
context.Dr. Kanta Subbarao, director of the WHO Collaborating Centre
for Reference and Research on Influenza and Professor in the
Department of Microbiology and Immunology at the University
of Melbourne, and Dr. Stanley Perlman, Professor in the Depart-
ments of Microbiology and Immunology and Pediatrics at the
University of Iowa, both reviewed their work and that of others
in animal models developed for SARS-CoV-1 and MERS-CoV. The
lessons from these models can inform the development priorities
for useful SARS-CoV-2 animal models to address both efficacy
and safety.
In inbred mouse strains, SARS-CoV-1 replicates efficiently in the
respiratory tract and can cause pneumonitis, but clinical signs and
pneumonia were only observed in old BALB/c mice [10]. Subse-
quent passage of SARS-CoV-1 through mouse lungs resulted in
the isolation of virus that caused severe disease in both young
and old mice [11,12]. This virus was used in many subsequent
studies. Ferret models of SARS-CoV-1 also demonstrate virus repli-
cation in respiratory tracts with induction of a neutralizing anti-
body response but also demonstrated little evidence of clinical
disease [13]. Hamsters, in contrast to mice and ferrets, demon-
strate high levels of viral replication, develop pneumonitis, and
can be shown to have clinical signs of disease [14]. Following the
identification of human ACE2 as the receptor for SARS-CoV-1,
transgenic murine models expressing human ACE2 receptor
(hACE2) were developed and shown to develop mild pulmonary
disease. Of note, these mice also developed lethal viral encephali-
tis, attributed to viral spread through the olfactory nerve, despite
the relative scarcity of hACE2 expression in the brain which may
have relevance to SARS-CoV-2 disease [15].
Efficacy of several SARS-CoV-1 vaccines was evaluated in these
models with spike (S) protein based vaccines demonstrating neu-
tralizing antibody and protection against pulmonary replication
of the challenge virus in mice and hamsters [16]. For DNA vaccine
studies, it was shown that candidate vaccines encoding the S pro-
tein conferred antibody mediated protection from challenge in
mice and that vaccines encoding the N protein induced humoral
and cellular immunity [17,18]. For vectored vaccines expressing
SARS-CoV-1 proteins, it was shown that viral proteins were
expressed in mice, ferrets, and hamsters. In these studies, neutral-
izing antibodies were elicited by B/HPIV3, VSV, rabies, MVA and
adeno viruses expressing S protein, that protected against SARS-
CoV-1 replication in lungs of challenged animals. However, one
MVA vaccine expressing the S-protein did not protect against
infection [16].
In contrast to SARS-CoV-1, inbred mice were found to be resis-
tant to MERS-CoV, thus infection was studied by creating models
that expressed the MERS receptor, human DPP4 (hDPP4). Ad5-
hDPP4 transduced mice could be infected with MERS virus but
infection was associated with minimal clinical disease except in
immunocompromised mice that developed weight loss after infec-
tion. Of note, hDPP4-transgenic mice developed lethal viral
encephalitis with concurrent inflammatory changes on histopatho-
logical examination of the lung, similar to hACE2-Tg mice with
SARS-CoV-1. Subsequently, investigators developed mice
‘‘knocked-in” for expression of hDPP4 and after virus passage in
these mice, identified mouse-adapted MERS strains that caused
more severe disease and increased histopathology with more pul-
monary edema than those infected with the original MERS strain
[19]. Importantly, mice without functional T cells, such as
RAG1-/- and TCR alpha-/-, had delayed viral clearance whereas
mice that could not produce antibodies, muMT mice, did not show
delay in clearance. Similar models were developed by CRISPR/Cas9
mutagenesis of two residues in the mouse ACE2 molecule, fol-
lowed by mouse adaptation with serial passage, leading to an ARDS
model of lethal infection [20,21]. Taken together this evidence sup-
ports the notion that T cells are important in viral clearance for
MERS [22].
Non-human primate (NHP) models have also been established
for both SARS-CoV-1 and MERS-CoV. There was evidence of upper
respiratory and lower respiratory tract SARS-CoV-1 replication in
African green monkeys to a greater extent than in cynomolgus
macaques, and least in rhesus macaques, with little evidence of
clinical disease in all three species [23]. Of note, consistent with
findings in older humans and mice, increased pathology has been
documented in aged cynomolgus macaques with SARS-CoV-1 wild
type infection [24]. There is some controversy on the disease sever-
ity in the MERS models with different groups seeing different
levels of pathology. This has not been resolved [25,26].3. Enhanced disease following SARS-CoV-1 vaccines
Both vaccine efficacy and safety have been studied in animal
models with many SARS-CoV-1 candidate vaccines. The group of
experts discussed how the vaccine models were utilized to charac-
terize the response of specific vaccines and to examine both dis-
ease enhancement and antibody dependent enhancement (ADE)
signals.
There is evidence for disease enhancement in vaccinated ani-
mals after challenge with live virus in multiple studies with
SARS–CoV-1 vaccine candidates as summarized in Table 1. We
are limiting our comments in this report to data in animal models
and not discussing in vitro data except to mention that there is
some evidence of ADE in human primary monocytes [27,28]. Dif-
ferent animal models exhibit different pulmonary pathology but
generally are characterized by cellular infiltrates including eosino-
phils. In this summary, we provide an overview of the consensus
opinion on vaccine related outcomes in animal models that were
of concern for risk of disease enhancement and could guide assess-
ments of SARS-CoV-2 vaccine candidates.Table 1
Evidence of enhanced disease in SARS-CoV-1 vaccine candidates.
Animal Model Vaccine
Murine1 VEE Replicon Particles expressing N protein
Murine2 Recombinant Vaccinia virus expressing N protein
Murine3 Inactivated Whole Virus
Murine4 Replicon Particles expressing S protein
Murine5 Inactivated Whole Virus and S protein vaccines
Ferret6 Recombinant Modified Vaccinia Virus Ankara (rMVA) expressin
NHP7 Modified Vaccinia Ankara (MVA) virus encoding full-length S p
Passive anti-S sera
NHP7 Inactivated Whole Virus
Passive Human SARS Antiserum
1 Young and senescent female BALB/c mice.
2 BALB/c mice.
3 Aged BALB/c mice.
4 Young and aged BALB/c mice.
5 Female BALB/c mice.
6 Mustela putorius furo, castrated males.
7 Chinese rhesus macaque.
y Acute hepatitis.In murine models, evidence for vaccine related disease
enhancement has been demonstrated for inactivated whole vac-
cine (with and without alum), vectored vaccine expressing N pro-
tein (but not seen with vectored vaccine expressing S protein in
same report), a replicon particle platform expressing S protein,
and a vectored vaccine expressing S proteins. In general, the
pathology described included pulmonary infiltrates often with
eosinophils observed. Th2 dominant responses were documented
in some reports by expression of Th2 driven cytokines [29–33].
In a ferret model, hepatitis was demonstrated in animals vacci-
nated with a recombinant modified vaccinia virus Ankara vaccine
expressing S protein and then challenged with virus [34] although
questions have been raised about this study [35].
Of note, mouse models have also shown evidence of enhanced
disease for inactivated and recombinant adenovirus 5-based
MERS-CoV vaccine [36,37].
Non-human primate models have also produced evidence of
enhanced disease after SARS-CoV-1 vaccine immunization. Chinese
macaques immunized with a modified vaccinia virus expressing S
protein then challenged with SARS-CoV-1 did not develop clinical
disease, but histopathology showed lung injury. This injury was
characterized by decreased wound healing, and increased pro-
inflammatory macrophages expressing IL-6, IL-8, and CCL2 [38].
This report also demonstrated that passively administered anti-S
antibody was associated with lung pathology after challenge with
the live virus although the mechanism may not be through Fc
receptor and thus not classic ‘‘ADE”. Of note, a second report sim-
ilarly demonstrates the effect with certain anti-S antibody prepara-
tions and without Fc involvement [39,40]. The relevance of these
reports remains unclear as there are multiple studies with admin-
istration of neutralizing monoclonal antibodies to different models
that did not induce disease enhancement. Other investigators have
reported absence of disease enhancement in both hamsters and
monkeys immunized with a whole inactivated vaccine although
these models differed in a number of ways, most notably by the
use of BPL (b-Propiolactone) instead of formalin for inactivation
of the virus [41,42]. Finally, we note that there has not been an
agreed upon positive control applied in these animal studies and
thus interpretations are hampered.4. SARS-CoV-2 murine and NHP models newly developed
Animal models with SARS-CoV-2 are being rapidly developed
by multiple research groups. Dr. Qin Chuan, Professor and DirectorAdjuvant Immunopathology Reference
– YES Deming 2006
– YES Yasui 2008
Alum YES Bolles 2011
– YES
– YES Sheahan 2011
Alum YES Tseng 2012
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g S protein – YESy Weingartl 2004
rotein – YES Liu 2019
N/A YES
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of the Institute of Laboratory Animal Science, Comparative Medi-
cine Center of the Peking Union Medical College presented data
on SARS-CoV-2 infection in both transgenic mice and rhesus maca-
que models.
Human ACE2 transgenic mice (hACE2 Tg) aged 4–6 weeks and
6–11 months of age were studied and hACE2 expression was
observed in lung, heart, kidney and intestinal tissues. Following
intranasal inoculation with SARS-CoV-2, weight loss was observed,
and viral RNA was detected in the lungs as well as in the intestine
[43].
Gross pathology demonstrated swollen and enlarged lungs with
moderate interstitial pneumonia. Histological studies documented
an accumulation of inflammatory cells including monocytes and
lymphocytes in alveolar interstitium, with thickening of alveolar
walls. SARS-CoV-2 S protein was detected by IHC in alveolar
macrophages and epithelia [43].
NHP were also infected with SARS-CoV-2 with 3 rhesus maca-
ques aged 3–4 years inoculated intratracheally and although no
fever was observed, weight loss and asthenia were seen on multi-
ple days. Viral RNA was detected from nasal and throat swabs and
to a lesser degree in anal specimens, peaking on days 3 to 7 and
lasting until day 11 post infection. One animal was euthanized
on day 7 for necropsy and viral RNA was detected in multiple
organs including CNS, skeletal muscle and heart. For the two sur-
viving rhesus macaques, positive neutralization titers were docu-
mented by day 11 post infection. There was radiographic
evidence of multiple ground glass opacities in the lungs on days
3, 5 and 7 post infection. Microscopically the lung lesions repre-
sented an acute interstitial pneumonia characterized by mild to
moderate thickening of alveolar septum, increased number of
macrophages, degeneration of pneumocytes and an inflammatory
cell infiltration. Presence of viral antigen was confirmed, predomi-
nately in alveolar monocytes and macrophages [44]. Analysis of
blood samples showed a decline in counts of total white blood
cells, lymphocytes and monocytes with no observed changes in
percentages. A decrease in both CD3 + CD4 + and CD3 + CD8 + T-
cell counts was observed. Importantly, these hematological find-
ings are similar to those seen in SARS-CoV-2 infected patients.
This model could serve as a critical tool for detailed studies of
pathogenesis and the evaluation of intervention strategies includ-
ing vaccines. Of note, following the meeting another group has
confirmed SARS-CoV-2 infection in rhesus macaques with viral
antigen detected in type I and type II pneumocytes and diffuse pul-
monary alveolar damage noted [45]. Experts agreed that these
models and others under development should be utilized to evalu-
ate vaccine candidates for any evidence of disease enhancement as
specified in later sections.5. COVID-19 vaccine design considerations for efficacy and
safety
5.1. Structure and function of S glycoproteins in coronavirus
Design of safe and effective COVID-19 vaccines can be informed
by knowledge of previous coronavirus vaccine development activ-
ities and shared elements of viral pathogenesis for non-
coronaviruses such as RSV. Specific epitope targets for potent neu-
tralizing antibody, platforms for inducing both neutralizing anti-
body and effective T cell responses, and adjuvants for improving
immunogenicity were presented at the conference. We review first
the structure and function of the major target of COVID-19 vacci-
nes, spike (S) glycoprotein.
Ralph Baric PhD, Professor in the Department of Epidemiology
at the University of North Carolina Chapel Hill School of Medicine
presented a review of the structure and function of coronavirus(CoV) S glycoprotein highlighting priorities for the development
of vaccine and immune therapeutics. There is a long history of
emerging CoVs with acceleration of cross-species movement and
emergence of highly pathological strains in the last 16 years,
including SARS-CoV-1, MERS-CoV, and SARS-CoV-2, and this trend
is likely to increase in the future. Phylogenetic relationships within
CoVs have been established, and Group 2B includes SARS-CoV-1
and SARS-like CoVs including SARS-CoV-2, BtCoV WIV1 and BtCoV
SHC014. Similarly, Group 2C are MERS-like CoVs which are also
poised for human emergence. Within Group 2B, known SARS-like
CoVs are divided into high or low pre-epidemic potential. High risk
features include use of ACE2 for cell entry, growth in primary
human airway cells, causing ARDS, causing age-related disease
severity, and escape from existing immune therapeutics. Drivers
of CoV evolution include the high mutation rate of the RNA-
dependent RNA polymerase paired with the regulated fidelity com-
plex. CoVs also demonstrate high rates of RNA recombination as
during mixed infection up to 25% of progeny are recombinant,
and modular evolution allows CoVs to swap whole genes or por-
tions of key proteins between strains. The S protein itself, which
regulates host range, tissue tropism, and transmissibility, can toler-
ate a high mutation rate while retaining its function.
The organization of the SARS-CoV-2 genome has been eluci-
dated and SARS-CoV-2, like SARS-CoV-1, has been shown to use
hACE2 for cell entry. Group 2B viruses have fourteen contact inter-
faces between their S protein and ACE2. Variation across the inter-
face sites can facilitate orthologous species ACE2 receptor usage,
since as few as seven interface sites are needed for entry. The pre-
fusion structure of the S glycoprotein has three major antigenic
domains, receptor binding domain (RBD), N terminal domain
(NTD), and S2. Epitopes on SARS-CoV-1 RBD have been identified
as targets for neutralizing antibodies. Analyzing the variations
and conserved regions in the S protein of Group 2B SARS-like CoVs,
shows conserved sites on the S2 region that could be targeted in
broad-based therapeutics against multiple CoVs.
Dr. Baric stressed that there is a large reservoir of SARS-like and
MERS-like CoVs poised for emergence in humans. Two priorities
are immediate vaccine candidates specific for SARS-CoV-2 and
development of broad-based vaccines protective against antigeni-
cally distinct CoVs destined to emerge in the future. Key priorities
for the development of a SARS-CoV-2 vaccine include characteriza-
tion the SARS-CoV-2 neutralizing epitope map, identification of
broadly cross-reactive neutralizing epitopes, identification of puta-
tive enhancing epitopes that might potentiate disease in vivo, iden-
tification of key T cell epitopes across outbred populations, and
determination of correlates of protective immunity.
5.2. Preserving neutralization sensitive epitopes on spike proteins
Barney Graham, MD PhD, Deputy Director of the NIH Vaccine
Research Center presented data on the immunogenicity and neu-
tralizing efficacy of truncated spike (S) antigens, with a focus on
SARS-CoV-2. Class I fusion proteins (such as S protein) are common
among enveloped viruses including RSV, parainfluenza viruses, and
coronaviruses and have been successfully stabilized in their pre-
fusion conformations. This approach has been shown to preserve
neutralization-sensitive epitopes, avoid antibodies that are non-
neutralizing, and improve expression in transfected cells, thus aid-
ing in manufacturing and immunogenicity of gene-based vectors.
The S proteins of SARS-CoV-1 and MERS-CoV have both been suc-
cessfully stabilized by introducing two proline residues to the top
of the central helix, preventing heptad assembly and stabilizing the
S2 region and the entire S protein as a result (Fig. 1) [46].
The SARS-CoV-2 S protein structure was solved shortly after its
emergence and shows similar structure and mobility as the SARS-
CoV-1 S [47]. The timing from first knowledge of SARS-CoV-2 to the
Fig. 1. 2P mutation stabilizes MERS and SARS CoV S; improves expression, prefusion structure, and immunogenicity.beginning of the Phase 1 study was a remarkable sixty-five days.
The advantages of mRNA vaccines include ability to create a highly
precise type of protein to elicit the correct antibodies, to elicit T cell
responses that are Th1 predominant, and the rapidity of manufac-
turing. Of course, disadvantages include the novel nature of both
mRNA and DNA vaccines without any licensed vaccine with either
technology to date and lack of experience for mass production.
Therefore, multiple platforms for SARS-CoV-2 are under develop-
ment that mitigate against some of the potential disadvantages
of nucleic acid vaccines.
6. Effects of adjuvants on immune response and implications
for COVID-19 vaccines
Although mRNA and DNA vaccines elicit T cell responses with-
out adjuvants, adjuvants may be important for subunit and whole
cell inactivated vaccines to increase their immunogenicity and
drive an immune response that could limit the risk of disease
enhancement. Multiple SARS-CoV-2 vaccines are in development
including vectored vaccines, whole cell inactivated vaccines, and
recombinant protein vaccines. The experts discussed how the
choice of adjuvants will be important for both efficacy and safety
with these platforms.
Dr. Arnaud Didierlaurent from the Centre of Vaccinology at the
University of Geneva presented background on the effects of differ-
ent adjuvants on animal and human immune responses. Several
adjuvants are now being used in commercial vaccines or are in
clinical development [48]. Oil-in-water emulsions such as MF59
or AS03 have been shown to increase the breadth of the antibody
repertoire, binding affinity and affinity maturation when compared
to unadjuvanted vaccines [49,50] In human studies with influenza
vaccines, H5N1 vaccine adjuvanted with MF59 (squalene-based
emulsion) increased the levels of H5-specific antibody for sub-
classes IgG1 and IgG3 and the binding to FccR2 but not to FccR3
when compared to alum adjuvanted vaccines. This demonstrates
that the use of an adjuvant can skew the functionality profile of
antigen-specific antibodies, with the potential to activate different
innate effectors based on their FccR expression [51]. Use of
squalene-based emulsion vaccines for influenza have also been
shown to increase CD4 + T cell response frequencies and cross-
reactivity. Even if pre-existing cross-reactive antibodies are pre-sent prior to immunization, such adjuvants could activate naïve
B cells and promote the adaptability of memory B cells [52–55].
In addition to antibodies, adjuvants can promote cellular
responses. Human malaria challenge studies provided early evi-
dence that the choice of adjuvants (combined with the malaria
antigen RTS,S) was critical in achieving optimal protection and
highlighted the importance of cellular response [56]. More
recently, studies with Hepatitis B Surface Antigen (HBs) vaccine
adjuvanted with AS01, AS03, AS04 or alum showed that vaccines
formulated with AS01 and AS03 induced the highest antibody
levels while AS01 promoted best HBs-specific CD4 T cell response
[57]. These differences were associated with the magnitude of the
initial inflammatory response triggered by the different adjuvanted
formulations [57,58]. Interestingly, although the level of CD4 T cell
response was lower in the alum group compared to the AS01
group, both adjuvants led to similar memory subset profiles and
cytokine production profiles (polyfunctionality) and neither
induced Th2 cytokines nor a CD8 induced response upon peptide
restimulation. This indicates that use of alum may not necessarily
lead to Th2 skewing in humans. Recently a number of systems biol-
ogy studies have revealed that specific early signatures (e.g.,
interferon-dependent pathways) induced by adjuvanted vaccines
are often associated with protective responses [59] but the impact
of these early signals on functional features of antibodies and the
quality of T cell response are not well established yet.
Although adjuvant selection is best performed in early clinical
studies, animal models could be useful in determining the immune
profile of adjuvanted vaccines. NHP models are well-established to
assess immune responses to vaccination and elicit immune
responses in closer parallel to humans than mice. For example, in
non-human primates, adjuvant choice affects antibody half-life,
antibody glycosylation and antibody binding to FccRs, indicating
effects on both antibody quality and function, like what is observed
in humans [60]. When adeno-based vectored vaccines are given to
humans or NHPs, both groups develop similar antibody function
profiles. Additionally, NHPs and humans tend to show similarities
in terms of ‘‘ranking” of adjuvants and innate immune pathways
triggered by adjuvants. Overall, NHPs could be utilized to evaluate
COVID-19 vaccine candidates with and without adjuvants and
guide in the selection of vaccines that elicit desired attributes that
could reduce the risk of vaccine-mediated enhanced disease.
Given the unprecedented demand for an effective vaccine, the
use of adjuvants may be critical for subunit vaccines in providing
antigen-dose sparing, increased immunogenicity, breadth and
duration of response, potentially eliciting cross-protection against
new CoV strains and minimizing the risk of enhanced disease.
7. Consensus considerations on the assessment of the risk of
disease enhancement with COVID-19 Vaccines:
Following the presentations, attendees participated in discus-
sion of the suggested consensus statements and all attendees were
asked to comment on the draft statements available online. These
comments were reviewed and discussed again on the second day
of the meeting and resulted in the summary consensus statement
that follows.
Murine models for assessment of vaccine-related disease
enhancement
 SARS-CoV-2 has a low affinity for murine ACE2 receptor and
murine models will require the use of hACE2 transgenic mice,
preferably with a ‘knock-in’ approach. Preliminary data indicate
the possibility of infecting hACE2 transgenic mice with demon-
stration of viral replication and mild lung lesions. Mouse adap-
tation of SARS-CoV-2, as done with SARS-CoV-1, will likely be
required to obtain a virus that causes more severe disease in
mice. Models that develop acute lung injury with some lethality
and that mimic the human condition will be important for eval-
uating vaccine safety.
 Previous studies from SARS-CoV-1 and MERS-CoV indicated
that some vaccines, especially those using whole inactivated
virus, could enhance the disease induced in mice challenged
with SARS-CoV-1 or MERS-CoV. The lung lesions were highly
inflammatory, with a dominance of eosinophil infiltration and
occurred in animals despite presence of a neutralizing antibody
response and reduced challenge virus replication in the lungs.
Such studies have not yet been completed for SARS-CoV2.
 In mice, this immunopathology was considered a consequence
of a dominant Th2 type response to the vaccine antigens. It
was not seen after including adjuvants (e.g. CpG) in the vaccine
or other vaccine formulations known to drive immune
responses towards Th1. The timing of challenge after vaccina-
tion may be critical. It would be of major interest to explore
the outcome following challenge at later timepoints when anti-
bodies are significantly decaying.
 One should be aware of the potential confounding effect of cell-
culture excipients in the vaccine and challenge strain material.
It is known that impurities such as fetal calf serum in the pre-
clinical vaccine preparation may induce eosinophil influx in
any mouse model if the challenge strain also contains the same
excipients.
 In these models, characterization of the immune response to the
candidate vaccine (e.g., IgG isotypes, Th2 markers) may have
some predictive value.
 Other small animal models which can be infected by SARS-CoV-
2 can be considered (e.g. ferret, hamster). Development of small
animal models of severe disease will also inform studies of
vaccine-enhanced disease.
Non-human primate models for assessment of vaccine-
mediated enhanced disease
 Non-human primates (NHP) are of primary interest in view of
their ACE2 homology with hACE2. Preliminary studies indicate
the possibility of inducing some COVID-19 lung pathological
features after infection, without clinical signs, in Rhesus maca-ques. African Green monkeys may be more susceptible to
COVID-19, but the model suffers from some limitations (e.g.
access, genetic polymorphism).
 Previous studies with SARS candidate vaccines have suggested a
risk of enhanced pathology in NHPs after viral challenge. Eosi-
nophilic infiltrates were not prominent. The mechanism is still
incompletely defined but there is evidence for a role of non-
neutralizing antibodies. Non- or incompletely neutralizing anti-
bodies may contribute to:
o the formation of pathogenic immune complexes and
o Fc-mediated viral capture by monocytes/macrophages that
may favor excessive T-cell activation and inflammation.
 Enhanced pathology was seen following passive transfer of IgG
from immunized NHPs
General considerations on animal models
 Although existing animal models of COVID-19 imperfectly
reproduce the human disease, they appear useful for assess-
ing the risk of disease enhancement. Vaccine responses are
closer to human responses in NHPs than in mice. Therefore,
it is likely that data obtained from NHP studies are more
significant. However, there is an urgent need to standardize
the NHP model (read-out of disease enhancement, timing
of challenge, age) and to include appropriate controls (i.e.,
a vaccine that induces enhanced pathology and disease)
and a sufficient number of animals to be confident of find-
ings in outbred species. It is important to control for poten-
tial co-infection, including with other coronaviruses, in all
non-SPF models.
 Potential markers of safety in these animal models could
include:
o the relative levels of neutralizing vs non-neutralizing
antibodies,
o antibody affinity,
o T-cell response profile,
o quantitative virology in the upper and lower respiratory tract
o characterization of lung histopathology with immunohisto-
chemistry for viral antigen and immune cell markers.
 Passive transfer in NHPs of human antibodies generated during
Phase 1 trials, followed by viral challenge could be considered
to assess the risk of disease enhancement.
 Challenge of immunized animals with a closely related heterol-
ogous CoV strains may assess the risk of enhancement during
future outbreaks.
 In case of disease enhancement, in-depth studies in animal
models may give some indications on the mechanism of
immunopathology. They can inform human trial designers on
the critical immunological risk markers to be monitored in
Phase 1 trials.
 Based on previous experience with SARS and other viral dis-
eases, it may be useful to evaluate the risk of disease enhance-
ment for COVID-19 vaccines (particularly those including whole
virions or N protein) in an established NHP model before
advanced clinical development.
During the Vaccine Design session, the group of Experts sug-
gested that consideration should be given to the following:
 Caution should be observed when developing vaccines to avoid
inducing predominant Th2 responses and non-neutralizing
antibodies.
 Vaccines inducing strong neutralizing antibodies, predominant
Th1 responses and balanced CD4/CD8 and polyfunctional T cell
responses are less likely to induce immunopathology.
 Given what will be the unprecedented demand for an effective
vaccine, the use of adjuvants may be critical for sub-unit vacci-
nes in providing increased immunogenicity, breadth of
response, dose sparing, duration of response, potentially
cross-protection against new CoV strains, and possibly mini-
mize the risk of enhanced disease. Preference should be given
to Th1-driving adjuvants with an established safety profile in
humans.
 Understanding the role cross-reacting antibodies from prior
coronavirus infections may have on natural disease caused by
SARS-CoV-2 or if they influence the risk of enhanced disease fol-
lowing vaccination may inform vaccine design.
 Data are needed on whether antibody waning could increase
the risk of enhanced disease on exposure to virus in the long
term.
It was the opinion of the Experts that animal data to support
clinical development could address:
 Post-vaccination (neutralizing) antibody responses, and T cell
analysis to demonstrate a Th1 response.
 Post-vaccination challenge data from NHPs with careful evalua-
tion for immunopathology and quantitative virology in the
animals.
 Small animal data may also provide important supporting evi-
dence of safety, and hamster, ferret and mouse models are likely
to be available for developers.
 Where possible, immunopathology experiments with a positive
control (e.g., formalin inactivated alum-adjuvanted SARS-CoV-1
or SARS-CoV-2 vaccine) and a mock-immunized negative con-
trol will provide best guidance. It was felt that it will be impor-
tant to establish broadly accepted endpoints and scoring
systems to allow comparison of various vaccine candidates.
WHO is working on this issue.
 For vaccine constructs likely to induce a predominant Th2
response, the group felt that animal studies should be consid-
ered before entering human Phase 1 trials in more than one ani-
mal species including NHPs where possible. It was noted that
the absence of a Th2 response does not eliminate the risk of
enhanced disease.
 For vaccine constructs which are already known to induce neu-
tralizing antibody and Th1 responses, it was the consensus of
the group that while Phase 1 studies are cautiously proceeding
with careful review of safety data, animal studies run in parallel
could provide useful information for the further clinical
development
 Suggestive data in animal models should not by default prevent
clinical development of vaccine candidates; potential risk
should be thoroughly evaluated by developers and regulators
on a vaccine product-specific basis.
Regarding Phase 1 clinical trials, it was the opinion of the
Experts that:
 Since not all studies that have begun or are about to begin will
prescreen to determine preimmunization serostatus of partici-
pants, although this shall be determined retrospectively, appro-
priate baseline blood specimens should be obtained and stored.
Because the virus is spreading rapidly, such specimens will
allow assessment of the immune response in both seronegative
and seropositive persons as both are likely to be vaccinated.
 Level of neutralizing antibodies and determination of the rela-
tive ratio of binding to neutralizing antibodies will be important
to assess the potential risk of enhanced disease. Also, detection
of initial priming that includes CD8 T cells and/or a CD4 Th1
biased response is likely to mitigate the risk of disease enhance-ment. Determination of memory responses will be useful, par-
ticularly if SARS-CoV-2 continues to circulate.
 Consideration should be given to the use of post-vaccination
sera from vaccinees which could be used for antibody transfer
studies in animals to look for enhanced disease and for evidence
of cross-protection against other coronaviruses.
 Monitoring for enhanced disease in immunized participants
may require longer follow-up than is usual in Phase 1 trials
but need not delay Phase 2 trials.
 Investigators on the call requested frequent updating with both
preclinical and evolving clinical data that are being developed
by the different academic and industrial developers to help in
decision-making about the various vaccine clinical trials. Crea-
tion of a central information hub was encouraged for this
purpose.
 Participants on the call expressed the need for standardization
of protocols, data collection forms, critical assays (including
reagents) and biobanking of samples from initial clinical trials
to allow future re-assay once standards are agreed to and
enable comparison of results across trials
Concluding remarks
 The group of Experts considers that the demonstration of some
disease enhancement with any candidate vaccine after viral
challenge in animal models should not necessarily represent a
no-go signal for deciding whether to progress into early trials
in clinical development of a COVID-19 vaccine.
 Continuous monitoring of this risk during clinical trials in an
epidemic context will be needed.
 Each observed effect should be discussed by the developers
with their regulators who will ultimately define the actual
requirements for clinical studies.
The considerations in this document should be interpreted as
general scientific remarks based on current knowledge to inform
a research agenda that could be beneficial for vaccines in develop-
ment. These considerations are not of a regulatory nature and can-
not in any sense replace the need for proper regulatory
consultations on the requirements for vaccines clinical trials. Vac-
cine developers are therefore encouraged to seek individual scien-
tific advice from regulatory authorities.Disclaimer
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